Blocking PD-1/PD-L1 through mAb binding activates tumor-specific CD8+ T cells by allowing the activation of the TCR and CD28 co-stimulation with DCs, both in the TIME and the tumor-draining lymph node (tdLNs) [55]. Here, CD28 is linked to neoplasm.